Table of Contents
Dosage (adults)
Renal/hepatic impairment
Other special populations
Children and adolescents
Method of administration
Duration of administration
Prolongation of QTc interval and potentially QTc-prolongation-related clinical conditions
Hypersensitivity / allergic reactions
Severe liver disorders
Serious bullous skin reactions
Patients predisposed to seizures
Peripheral neuropathy
Psychiatric reactions
Antibiotic-associated diarrhoea incl. colitis
Patients with myasthenia gravis
Tendon inflammation, tendon rupture
Patients with renal impairment
Vision disorders
Prevention of photosensitivity reactions
Patients with glucose-6-phosphate dehydrogenase deficiency
Patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Patients with pelvic inflammatory disease
Patients with special cSSSI
Interference with biological tests
Patients with MRSA infections
Paediatric population
Interactions with medicinal products
Changes in INR
Interaction with food
Pregnancy
Lactation
Mechanism of action
Effect on the intestinal flora in humans
Mechanism of resistance
In vitro Susceptibility Data
Absorption and Bioavailability
Distribution
Metabolism
Elimination
Tablet core:
Film coat:
Polypropylene/aluminium blisters
Aluminium/aluminium blisters
Link to this document from your website:http://www.medicines.ie/medicine/4362/SPC/Avelox+400mg+Film-coatedTablets/